CSTL — Castle Biosciences Share News
0.000.00%
Last trade - 00:00- $1.03bn
- $776.11m
- $344.23m
Brief: FDA Grants Breakthrough Device Designation To Castle Biosciences’ Decisiondx-Melanoma Test
Brief: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases
U.S. RESEARCH ROUNDUP-Levi Strauss, Myriad Genetics, Palo Alto
Castle Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Castle Biosciences To Acquire Previse
Brief: Castle Biosciences Q1 Basic EPS USD -0.9
Castle Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Castle Biosciences Q4 Revenue USD 86.311 Million Vs. IBES Estimate USD 81.9 Million
Brief: Castle Biosciences's Tissuecypher Barrett's Esophagus Test Receives New York State Department Of Health Approval
Brief: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule
Castle Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP-Cigna, Marriott, Ralph Lauren
Brief: Castle Biosciences Q3 Net Income USD 2.269 Million Vs. IBES Estimate USD -100.9 Thousand
U.S. RESEARCH ROUNDUP- Coinbase Global, Meta, Union Pacific
Brief: Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
Castle Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Castle Biosciences Q2 Net Income USD 8.92 Million Vs. IBES Estimate USD -9.23 Million